Immunoassay Interference by Endogenous Antibodies, 1st Edition
This guideline discusses the nature and causes of interfering antibodies, as well as their effects on immunoassays and mechanisms by which interference occurs. Methods to identify and characterize the interferences are addressed along with assessment of methods used to eliminate interference.
This document is available in electronic format only.
Members: $54.00 → $153.00Nonmembers: $180.00
Chairholder: Joan H. Howanitz, MD
Date of Publication: February 25, 2008
Order Code PDF: ILA30AE
ISBN Number: 1-56238-658-1
Order Code Print: print not available
I/LA30 Additional Details
The U.S. Food and Drug Administration (FDA) has evaluated and recognized this approved-level consensus standard for use in satisfying a regulatory requirement.
This archived document is no longer being reviewed through the CLSI Consensus Document Development Process. However, this document is technically valid as of September 2016. Because of its value to the laboratory community, it is being retained in CLSI’s library.